AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00740116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl solution
Description: 0.9% NaCl solution; 0.15 ml/kg body weight added to 100 ml 0.9% NaCl solution. The volume is given intravenously immediate before skin incision at surgery.
Study NCT02153983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6Mg Cap
Description: Colchicine 0.6 mg given twice daily
Study NCT02153983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsules given
Description: Placebo capsules given twice daily
Study NCT01922869 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flavonoids
Study NCT01286025 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: video case modality
Description: Patients whose case histories are pathophysiologically illustrative will be recruited, and interviewed on video. Their stories will be edited and divided into sections, and combined with the patient's laboratory, imaging, and pathological reports when appropriate
Study NCT01286025 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text case modality
Description: Patients whose case histories are pathophysiologically illustrative will be recruited, and interviewed on video. Their stories will be edited and divided into sections, and combined with the patient's laboratory, imaging, and pathological reports when appropriate. The transcript of these video-recordings will form the basis of the text-based case presentation modality.
Study NCT03757936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX04
Description: Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection
Study NCT03757936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection
Study NCT04870294 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Teeth treated with composite resin, control group
Description: The teeth grouped in group R were treated with composite resin restoration without liner material.
Study NCT04870294 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Teeth treated with lining, pulp wall with PBS DTA® cement and composite resin restoration
Description: The teeth grouped in group D received PBS CIMMO DTA® as indirect capping material of the cavity, followed by restoration of composite resin.
Study NCT03350503 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof IQ Toric A-code IOL
Description: Intended to provide visual acuity, including astigmatism correction, over the lifetime of the cataract patient
Study NCT03350503 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Removal of cataractous lens and implantation of IOL
Study NCT01757119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tardyferon 80 mg
Description: Oral administration (2 tablets)
Study NCT00016952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00016952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT00016952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT00834912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride
Description: 1x300mg Tramadol Hydrochloride (HCl) tablet (Confab Laboratories), fasting condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
Study NCT00834912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl
Description: 1x300mg Tramadol Hydrochloride (HCl) tablet (Confab Laboratories), fed condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
Study NCT00834912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl
Description: 1x300mg Tramadol Hydrochloride (HCl) tablet (Trillium Healthcare) fasting condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
Study NCT02153983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6Mg Tab
Description: Open-label colchicine
Study NCT01596790 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood analysis by EPISPOT and Cellsearch
Description: For each patient, we will perform a counting of CTC before chemotherapy and then at different time points after chemotherapy, using both technologies: EPISPOT and CellSearch®.For the EPISPOT, we will need 15 mL of peripheral blood on EDTA tubes. For each patient, five blood samples will be done: D0, D14, D28, D42 and D56. These different time points will help us to determine when the best moment is for the evaluation of the CTC with this technology.For the CellSearch®, we will need 10 mL of peripheral blood on a specific CellSave tube. Only two samples will be perform: D0 and D28 because Cohen et al. (2008) reported that the best appropriated moment to appreciate the CTC progression is between 3 and 5 weeks after the initiation of the treatment.
Study NCT01397409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-150998
Description: AGN-150998 Intravitreal injection.
Study NCT02489097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous Oxide
Description: Administration of a concentration of 70% Nitrous Oxide with 30% Oxygen in the anaesthetic gas mixture
Study NCT02489097 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of a concentration of 70% Air with 30% Oxygen in the anaesthetic gas mixture
Study NCT02253004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Single oral administration of active or placebo one week apart
Study NCT03240588 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurostimulation System
Description: Spinal cord stimulation
Study NCT01063465 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early weightbearing
Description: Patients in the intervention group are after 2 weeks supposed to remove the cast twice a day and use a special training pedal for 5 weeks (until cast removal).
Study NCT01397409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: Ranibizumab 0.5 mg given by intravitreal injection.
Study NCT01397409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Injection
Description: Stage 3: Sham injection at Weeks 12 and 16.
Study NCT01866891 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Three months of regular perdialytic physical activity (cycling)
Description: Cycling, in lying position, at a rate of thirty minutes per dialysis session (three a week), regardless of performance
Study NCT05021159 — intervention group
Intervention type: OTHER
Intervention: MTX, (but the investigator is not using any intervention, the participants are already taking it in their treatment protocol and the investigator is just analyzing p-gp expression)
Description: the investigator is not using any intervention, the participants are already taking it in their treatment protocol and the investigator is just analyzing p-gp expression
Study NCT00507312 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HD medical device (ViScope)
Description: Device
Study NCT03909074 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 36-71 months old children-experimental EV71 vaccine.
Description: Two doses experimental EV71 vaccine at the 0, 30 days vaccination schedule.
Study NCT00507312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD medical device (ViScope)
Description: Device
Study NCT00507312 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CSIRO device
Description: device
Study NCT00507312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CSIRO device
Description: device
Study NCT02253004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03694756 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TMEM-MRI
Description: TMEM MRI INFORMATION: Unilateral breast MRI will be obtained on a 3.0T whole body MRI scanner with a dedicated breast radiofrequency coil. The patient will be scanned in the prone position with an in-dwelling IV catheter for a single dose contrast agent injection.
Study NCT03694756 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: FNA
Description: FNA: The patients who are recruited prior to biopsy (Cohort A) will have had TMEM-MRI performed prior to biopsy. They will then present to radiology for ultrasound-guided core biopsy of the breast mass. FNA will be performed during this procedure. The FNA will be performed after local anesthetic is administered but prior to insertion of the core biopsy needle. FNA will be performed by the radiologist under direct sonographic visualization of the mass. Five passes will be obtained with a 25 gauge needle. The FNA material will be expelled into 1.5 ml Eppendorf tube containing phosphate buffered saline with EDTA.
Study NCT03425929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Intranasal administration, 24 international units (IU) oxytocin.
Study NCT02753361 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Description: In the second arm, ultrasound will be used to guide the regional block
Study NCT05646459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabidiol
Description: This group will locally apply cannabidiol to a posterior, localized 6-9 mm bleeding periodontal pocket.
Study NCT02793024 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Adolescents in the intervention arm will receive 3 face to face session about making smart shopping choices. The following 9 weeks will consist of utilizing social media to improve shopping choices.
Study NCT03425929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo nasal sprays contain identical ingredients except for the peptide itself.
Study NCT05646459 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: floss
Description: This group will use floss alone at the test site (posterior, localized 6-9 mm bleeding periodontal pocket).
Study NCT05646459 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: proxabrush
Description: This group will use floss alone at the test site (posterior, localized 6-9 mm bleeding periodontal pocket).
Study NCT02500043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: 35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle.
Study NCT02500043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 35 mg/m2/dose of placebo orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle.
Study NCT01548105 — intervention group
Intervention type: OTHER
Intervention: Blood draw for the study participants
Description: These will include:~* Procollagen 1-N propeptide levels (PINP)~* Matrix metalloproteinase (MMP9)~* Plasma Vitamin C levels
Study NCT02569190 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Walkbot
Description: Robot assisted gait training
Study NCT03909074 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 36-71 months old children-control EV71 vaccine.
Description: Two doses control EV71 vaccine at the 0, 30 days vaccination schedule.
Study NCT04536727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fit & Strong!
Description: The 8-week intervention will consist of the Fit \& Strong! program adapted to address the impact of exercise on enhancing positive affect and reducing negative affect and depressive symptoms. Exercise classes will meet three times per week for 90 minutes per session for eight weeks. Each class is divided into 60 minutes of strength training, flexibility, and cardiovascular exercise and 30 minutes of group education/discussion, which has been adapted to include affect-oriented content
Study NCT04536727 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wait list
Description: Participants randomized to the wait list group receive the 8-week Fit \& Strong! intervention after the intervention group has competed it and after the wait list group has provided their post-outcomes.
Study NCT03510117 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness
Description: Mindfulness
Study NCT03272919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm 1: Investigational INF
Description: INF utilizes three holds or positions, which widens tiny openings in arteries surrounding nerves and improves blood flow to targeted nerves. The improved blood flow in these nerves stimulates healing and reduces or even stops nerve pain.
Study NCT03272919 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Arm 2: standardized muscle stretching and strength
Description: subjects will receive a standardized program of muscle stretching and strengthening exercise under the supervision of treating physical therapist.
Study NCT03909074 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 6-35 months old children-experimental EV71 vaccine.
Description: Two doses experimental EV71 vaccine at the 0, 30 days vaccination schedule.
Study NCT02806752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: Intravitreal inject 0.5mg of Ranibizumab and 2mg of Triamcinolone Acetonide.
Study NCT03923647 — intervention group
Intervention type: DEVICE
Intervention: Laparoscopy
Description: Laparoscopic insertion with carbon dioxide via open technique at the umbilicus
Study NCT01457937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Interferon, Ribavirin, Boceprevir
Description: PEG IFN alfa 2b 1,5 ug/kg once weekly; Ribavirin (800-1400 mg / day)~or~PEG IFN alfa 2b 1,5 ug/kg once weekly; Ribavirin (800-1400 mg / day); Boceprevir (1.5 mcg / kg QW)
Study NCT01457937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon, Ribavirin, Boceprevir
Description: PEG IFN alfa 2b 1,5 ug/kg once weekly; Ribavirin (800-1400 mg / day)~or~PEG IFN alfa 2b 1,5 ug/kg once weekly; Ribavirin (800-1400 mg / day); Boceprevir (1.5 mcg / kg QW)
Study NCT03678571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Latrunculin A supplemented vitrification medium
Description: Vitrification of human oocyte in medium supplemented with Latrunculin A
Study NCT03323398 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-2416
Description: mRNA encoding human OX40L
Study NCT03323398 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: PD-L1 inhibitor
Study NCT03204682 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: Realization of a brain and medullary MRI to allow neuronavigation. Realization of 5 sessions of rTMS in 5 days during the first week then evaluation (physical examination, questionnaires) in consultation on post-stimulation. Then followed for 28 days in total through self-assessment of pain that will be filled daily on REDCap and last consultation on D28 for further evaluation
Study NCT05076461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron group received oral suspension of ondansetron as 0.15mg per body weight
Study NCT02806752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intravitreal inject 0.5mg of Ranibizumab.
Study NCT02806752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal inject 0.5mg of Ranibizumab.
Study NCT00344773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: 250mg tablet oral tablet once daily
Study NCT01730183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone marrow derived stem cells
Description: Intrathecal administration of autologous bone marrow derived stem cells upto a cell dose of equal or greater than 10(8)BMMNCs.
Study NCT02361710 — intervention group
Intervention type: PROCEDURE
Intervention: frozen embryo transfer
Description: comparison of groups according to their serum vitamin D levels on frozen embryo transfer day
Study NCT00500370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection (5mcg or 10mcg), twice a day
Study NCT00500370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous injection (equivalent volume to active dose), twice a day
Study NCT02905188 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GLYCAR T cells
Description: Five different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule.~The following dose levels will be evaluated:~DL1: 1x10\^7/m2~DL2: 3x10\^7/m2~DL3: 1x10\^8/m2~DL4: 3x10\^8/m2~DL5: 1x10\^9/m2~If DLTs are observed on DL1, patients will be enrolled on DL0 at 3x10\^6/m2 dose.~The first patient on each dose level has to be 14 days post T-cell infusion before the second patient can be enrolled.~The doses are calculated according to the actual number of GPC3-CAR transduced T cells.
Study NCT02905188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously
Study NCT02905188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously
Study NCT01437488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: * Cycle 1: 20 mg/m2 in 250cc NS via IV on Day 1 every 21 days~* Following cycles: 20 mg/m2 or escalated to 25 mg/m2 or reduced by 5 mg/m2 in 250cc NS via IV on Day 1 every 21 days at investigator's discretion~* Treatment continues until disease progression, intercurrent illness preventing further treatment, unacceptable adverse event(s), patient withdraws from the study, or changes in the patient's condition which render further treatment unacceptable in the judgment of the investigator
Study NCT01437488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neulasta
Description: 6 mg via SQ on Day 2 (24-48 hours post-cabazitaxel) every 21 days
Study NCT01437488 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT Scan
Description: CT scan of chest, abdomen, and pelvis to assess disease following every 3rd cycle of treatment (approximately every 9 weeks)
Study NCT01437488 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: Approximately 2 tablespoons of blood will be taken to test complete blood count, glucose, hematology, electrolytes, liver function, creatinine clearance, and a chemistry profile. This week be done weekly during the first cycle of treatment
Study NCT03629184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baloxavir Marboxil
Description: Baloxavir marboxil will be administered as oral suspension in a single dose on Day 1.~Oseltamivir matching placebo will also be administered as oral suspension twice daily (BID) for 5 days.
Study NCT03629184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Oseltamivir will be administered as oral suspension BID for 5 days. Participants receiving oseltamivir will also receive baloxavir marboxil matching placebo as oral suspension, single dose on Day 1.
Study NCT00742963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302
Description: TH-302 will be administered by IV infusion over 30-60 minutes on Days 1 and 8 of a 21-day cycle.~Dose escalation dose levels:~Dose level -1 (if needed): 180 mg/m2 Starting dose: 240 mg/m2
Study NCT03406338 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fasciectomy
Description: Surgical excision of Dupuytren cords causing finger joint contractures. Surgery done under regional or general anesthesia. Additional procedures (such as capsulotomy or skin graft) done if surgeon deemed necessary.
Study NCT03406338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum
Description: Injection of Collagenase into the Dupuytren cord after local anesthesia (nerve block) followed 24-48 hours later by finger manipulation after local anesthesia
Study NCT00437411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affective Self-Awareness workshop
Description: Affective Self Awareness intervention: 90 minute face-to-face consultation with the treating physician, then three 2-hour weekly small-group workshops involving education regarding Mind-Body connections, written emotional expression, meditation, and self-affirmation practices.
Study NCT02337192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Study NCT02337192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LED
Study NCT02337192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surfactant
Study NCT02337192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMSO + water
Study NCT02337192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Study NCT04453189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Participants will receive single dose of JNJ-64417184 in fed condition on Day 1 in assigned treatment sequence.